Connection Between the Early Phases of Kidney Disease and the Metabolic Syndrome

Manuel F. Landecho, a,∗ Inmaculada Colina, a Ana Huerta, a, b Ana Fortuño, b Guillermo Zalba, b and Óscar Beloqui a

∗Departamento de Medicina Interna, Clínica Universidad de Navarra, Pamplona, Navarra, Spain
A Área de Ciencias Cardiovasculares, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Navarra, Spain

ABSTRACT

Introduction and objectives: Advanced kidney disease is a major health problem due to its association with high cardiovascular morbidity and mortality. Early recognition of advanced kidney disease is the mainstay to avoid its progression. Since metabolic syndrome and insulin resistance are risk factors for both cardiovascular and advanced kidney disease, we investigated the relationship of early kidney disease (EKD) with metabolic syndrome and insulin resistance, and their association with surrogate markers of arteriosclerosis.

Methods: We studied 1,498 subjects. Insulin resistance was defined as HOMA ≥ 3.7 mmol (μU)/L2 and EKD as stages 1 and 2 of the NKF-KDOQI. Carotid intima-media thickness was used as a surrogate marker of arteriosclerosis.

Results: The presence of one trait of metabolic syndrome was associated with an odds ratio (OR) for EKD of 2.3 (95% confidence interval [CI], 1.18–4.48) that increased to 6.72 (95% CI, 3.56–13.69) in subjects with the syndrome. All the traits of the syndrome except low level of high-density lipoproteins showed an increased OR for EKD. Increasing HOMA was also directly correlated with higher OR for EKD, being as high as 3.89 (95% CI, 1.99–7.59) for subjects in the fourth quartile. Subjects with the syndrome plus EKD showed an increased intima-media thickness compared with those without kidney disease.

Conclusions: Insulin resistance and all metabolic syndrome traits except low level of high-density lipoproteins were significantly associated with an increased OR for EKD. Both metabolic syndrome and EKD were independently and additively related to the presence of surrogate markers of arteriosclerosis.

© 2010 Sociedad Española de Cardiología. Published by Elsevier España, S.L. All rights reserved.

Relación entre las fases precoces de la enfermedad renal y el síndrome metabólico

RESUMEN

Introducción y objetivos: La enfermedad renal avanzada es un importante problema sanitario por su alta morbimortalidad cardiovascular. La detección y el tratamiento precoces podrían ayudar a evitar su progresión. El síndrome metabólico y la insulinorresistencia se han implicado en la patogenia del daño renal avanzado. Nuestros objetivos son estudiar la relación entre la enfermedad renal precoz (ERP), el síndrome metabólico y la insulinorresistencia y valorar su asociación con marcadores de arteriosclerosis subclínica.

Métodos: El estudio incluyó a 1.498 pacientes. La insulinorresistencia se definió como HOMA ≥ 3.7 mmol (μU)/L2 y la ERP, como los estadios 1 y 2 de la NKF-KDOQI. Se utilizó el grosor intima-media carotídeo como marcador de arteriosclerosis subclínica.

Resultados: La presencia de un componente de síndrome metabólico se asoció con una odds ratio (OR) de ERP de 2.3 (intervalo de confianza [IC] del 95%, 1.18–4.48), que aumentó hasta 6.72 (IC del 95%, 3.56–13.69) en sujetos con el síndrome. Todos los componentes salvo el bajo valor de lipoproteínas de alta densidad se asociaron con OR elevada de ERP. El incremento del HOMA también se asoció en relación directa con la probabilidad de ERP, que llegó a OR = 3.89 (IC del 95%, 1.99–7.59) para los sujetos del cuarto cuartil. Los sujetos con síndrome metabólico y ERP mostraron un grosor intima-media carotídeo aumentado frente a aquellos sin enfermedad renal.

Conclusiones: La insulinorresistencia, el síndrome metabólico y sus componentes, salvo bajo valor de lipoproteínas de alta densidad, se asociaron significativamente con OR aumentada de ERP. El síndrome metabólico y la ERP se asociaron de forma independiente y aditiva con arteriosclerosis subclínica.

© 2010 Sociedad Española de Cardiología. Publicado por Elsevier España, S.L. Todos los derechos reservados.

SEE RELATED ARTICLE:
* Corresponding author: Departamento de Medicina Interna, Clínica Universidad de Navarra, Avda. Pío XII 36, 31008 Pamplona, Navarra, Spain.
E-mail address: mflandecho@unav.es (M.F. Landecho).
INTRODUCTION

Advanced kidney disease (KD) and end-stage KD have been recognized as important problems for public health given their increasing prevalence and poor prognosis.1 It is known that once KD starts, it usually progresses. Even so, in patients with advanced KD cardiovascular complications are more prevalent than progression to end-stage KD.2-4 Minimal reductions in the glomerular filtration rate is associated with an increase in vascular risk.4,6 Some of the factors associated with the progression of KD can be controlled medically and others cannot. Age is the most notable factor that cannot be controlled.5-11 The factors that can be controlled are the typical factors of vascular risk. The most important factors are high blood pressure, diabetes mellitus and insulin resistance (IR), obesity, and dyslipidemia. Together these make up the metabolic syndrome (MS). KD is divided into 5 stages,1 which can be grouped together in 2 blocks. On one side are the patients with analytical data showing kidney damage (microalbuminuria) and with a glomerular filtration rate >60 ml/min/1.73m² (stages 1 and 2; early KD [EKD]). On the other side are patients with an abnormal glomerular filtration rate, whether there is microalbuminuria or not (stages 3, 4 [advanced KD] and 5 [end-stage KD]).

MD is a collection of risk factors with a total and cardiovascular mortality described as approximately double that of the general population.12,13 This is despite the fact that a greater knowledge of the symptoms has led to significant improvements in the individual management of these patients. Furthermore, this is an increasingly prevalent disease.14-16 An aging and obese population are the most important factors associated with the increasing prevalence of MS.16 This tendency for the prevalence to increase, which has reached a pandemic level,17-18 has been confirmed in Spain.19-21 IR is the underlying metabolic defect of MS.

The hypothesis of this study was that MS and its traits could be associated with the early stages of KD. Furthermore, both diseases could have a synergistic effect on the development of arteriosclerosis. The objectives were to analyze the possible overall connection between MS, its traits, and EKD; assess the importance of each trait and IR in the presence of EKD; and assess EKD and MS as independent cardiovascular risk markers in the development of arteriosclerosis.

METHODS

In accordance with international guidelines, the patients included in the study were informed about the study and gave their written consent. The study was designed in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of the Clínica Universidad de Navarra (University Clinical Hospital of Navarra). The study was carried out with subjects who went to the hospital's Medical Examination Unit for a regular medical examination after fasting for 12 h.

The study population was recruited between May 1999 and January 2009. We assessed 2163 consecutive subjects that underwent a general medical examination. A complete medical history was collected in all the cases. Exclusion criteria were as follows:

- Present or past history of arterial disease (claudication, ischemic cardiomyopathy or history of stroke).
- Previous diagnosis of high blood pressure and/or diabetes mellitus.
- Glomerular filtration rate below 60 ml/min/1.73m² (KD stage 3 to 5).

After the exclusions, 1498 subjects signed the informed consent and were included in the study.

EKD was defined as stages 1 and 2 of the criteria set out by the National Kidney Foundation. Albumin/creatinine ratio (ACR) was determined in an isolated urine sample in order to identify microalbuminuria. Kidney damage was defined as a microalbuminuria between 17-300 mg/g for men and 25-300 mg/g for women.1 The MDRD (Modification of Diet in Renal Disease) formula was used to estimate the glomerular filtration rate.1

The modified ATP-III criteria by the American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI)22 were used to diagnose MS. Subjects with none of the AHA/NHLBI criteria were defined as the control population.

The Homeostasis Model Assessment (HOMA) index was used to measure IR. The IR cut-off point was set as a HOMA score of >3.7 mmol (µU)/l² on the basis of a preliminary study carried out on 50 control subjects with a body mass index <25 where the average HOMA score was 1.61 ± 0.696 mmol (µU)/l². The cut-off point corresponded to the average HOMA score of this preliminary sample plus 3 standard deviations. It coincided with previous publications on Spanish populations.23

The intima-media thickness (IMT) of the carotid artery was analyzed as a marker of subclinical arteriosclerosis in 1000 of the 1498 subjects in the initial study. All of the carotid IMT measurements were made with a Doppler ultrasound by experienced ultrasound specialists from the hospital’s Department of Radiology. The measurements were made with a 5-12 MHz linear transducer (ATL 500 HDI). The interobserver and intraobserver variations of the ultrasound specialists have been validated in previous studies by our group.24-26 The measurement was taken at 1 cm proximal to the bulb of each common carotid artery in plaque-free areas. The average value of both sides was used as the carotid IMT measurement. The cut-off point for abnormal carotid IMT was set at 0.75 mm. This point was chosen as it was the lower limit of the upper quartile of an in-house study carried out on 156 healthy control subjects. Furthermore, this cut-off point was the same as that published for a sample of Spanish males of the same age group as the average age of our study.27

The analytical measurements were carried out using standard laboratory techniques.

The results were expressed as the arithmetic mean ± standard deviation. Differences were considered to be statistically significant in all cases when P < .05.

The Shapiro-Wilks test and the Kolmogorov-Smirnov test (with the correction of Lilliefors) were used to analyze if a variable followed a normal distribution within a population. The Levene’s Test was used to analyze the equality of variances between the two samples.

The one-way ANOVA test, with the post-hoc Tukey B or Scheffé test, was used for the parametric samples, to compare the quantitative parameters between three or more experimental groups. The Kruskal-Wallis test followed by the Mann-Whitney U test was used for the post-hoc comparisons of non-parametric samples.

Abbreviations

ACR: albumin to creatinine ratio
EKD: early kidney disease
IR: insulin resistance
KD: kidney disease
MS: metabolic syndrome
The prevalence of EKD increased progressively and was statistically significant as the number of traits of MS increased. Of the subjects with no traits, 2.9% met EKD criteria. The prevalence increased to 7.4% when a subject had 1 trait, to 9.5% with 2 traits, and to 20% when diagnosed with MS (P trend < .001). Table 3 shows that the healthy control subjects’ risk of EKD, estimated using odds ratio (OR), increased in connection with the number of traits of MS.

The prevalence of EKD increased progressively and was statistically significant as the number of traits of MS increased. Of the subjects with no traits, 2.9% met EKD criteria. The prevalence increased to 7.4% when a subject had 1 trait, to 9.5% with 2 traits, and to 20% when diagnosed with MS (P trend < .001). Table 3 shows that the healthy control subjects’ risk of EKD, estimated using odds ratio (OR), increased in connection with the number of traits of MS.

Table 2 shows the general characteristics of the population studied.

Table 1 shows the general characteristics of the population studied. Of the 1498 subjects studied, 8.9% complied with EKD criteria. The prevalence increased progressively and was statistically significant as the number of traits of MS increased. Of the subjects with no traits, 2.9% met EKD criteria. The prevalence increased to 7.4% when a subject had 1 trait, to 9.5% with 2 traits, and to 20% when diagnosed with MS (P trend < .001). Table 3 shows that the healthy control subjects’ risk of EKD, estimated using odds ratio (OR), increased in connection with the number of traits of MS.

The prevalence of EKD increased progressively and was statistically significant as the number of traits of MS increased. Of the subjects with no traits, 2.9% met EKD criteria. The prevalence increased to 7.4% when a subject had 1 trait, to 9.5% with 2 traits, and to 20% when diagnosed with MS (P trend < .001). Table 3 shows that the healthy control subjects’ risk of EKD, estimated using odds ratio (OR), increased in connection with the number of traits of MS.

The prevalence of EKD increased progressively and was statistically significant as the number of traits of MS increased. Of the subjects with no traits, 2.9% met EKD criteria. The prevalence increased to 7.4% when a subject had 1 trait, to 9.5% with 2 traits, and to 20% when diagnosed with MS (P trend < .001). Table 3 shows that the healthy control subjects’ risk of EKD, estimated using odds ratio (OR), increased in connection with the number of traits of MS.

The prevalence of EKD increased progressively and was statistically significant as the number of traits of MS increased. Of the subjects with no traits, 2.9% met EKD criteria. The prevalence increased to 7.4% when a subject had 1 trait, to 9.5% with 2 traits, and to 20% when diagnosed with MS (P trend < .001). Table 3 shows that the healthy control subjects’ risk of EKD, estimated using odds ratio (OR), increased in connection with the number of traits of MS.

The prevalence of EKD increased progressively and was statistically significant as the number of traits of MS increased. Of the subjects with no traits, 2.9% met EKD criteria. The prevalence increased to 7.4% when a subject had 1 trait, to 9.5% with 2 traits, and to 20% when diagnosed with MS (P trend < .001). Table 3 shows that the healthy control subjects’ risk of EKD, estimated using odds ratio (OR), increased in connection with the number of traits of MS.

The prevalence of EKD increased progressively and was statistically significant as the number of traits of MS increased. Of the subjects with no traits, 2.9% met EKD criteria. The prevalence increased to 7.4% when a subject had 1 trait, to 9.5% with 2 traits, and to 20% when diagnosed with MS (P trend < .001). Table 3 shows that the healthy control subjects’ risk of EKD, estimated using odds ratio (OR), increased in connection with the number of traits of MS.

The prevalence of EKD increased progressively and was statistically significant as the number of traits of MS increased. Of the subjects with no traits, 2.9% met EKD criteria. The prevalence increased to 7.4% when a subject had 1 trait, to 9.5% with 2 traits, and to 20% when diagnosed with MS (P trend < .001). Table 3 shows that the healthy control subjects’ risk of EKD, estimated using odds ratio (OR), increased in connection with the number of traits of MS.

The prevalence of EKD increased progressively and was statistically significant as the number of traits of MS increased. Of the subjects with no traits, 2.9% met EKD criteria. The prevalence increased to 7.4% when a subject had 1 trait, to 9.5% with 2 traits, and to 20% when diagnosed with MS (P trend < .001). Table 3 shows that the healthy control subjects’ risk of EKD, estimated using odds ratio (OR), increased in connection with the number of traits of MS.

The prevalence of EKD increased progressively and was statistically significant as the number of traits of MS increased. Of the subjects with no traits, 2.9% met EKD criteria. The prevalence increased to 7.4% when a subject had 1 trait, to 9.5% with 2 traits, and to 20% when diagnosed with MS (P trend < .001). Table 3 shows that the healthy control subjects’ risk of EKD, estimated using odds ratio (OR), increased in connection with the number of traits of MS.

The prevalence of EKD increased progressively and was statistically significant as the number of traits of MS increased. Of the subjects with no traits, 2.9% met EKD criteria. The prevalence increased to 7.4% when a subject had 1 trait, to 9.5% with 2 traits, and to 20% when diagnosed with MS (P trend < .001). Table 3 shows that the healthy control subjects’ risk of EKD, estimated using odds ratio (OR), increased in connection with the number of traits of MS.

The prevalence of EKD increased progressively and was statistically significant as the number of traits of MS increased. Of the subjects with no traits, 2.9% met EKD criteria. The prevalence increased to 7.4% when a subject had 1 trait, to 9.5% with 2 traits, and to 20% when diagnosed with MS (P trend < .001). Table 3 shows that the healthy control subjects’ risk of EKD, estimated using odds ratio (OR), increased in connection with the number of traits of MS.

The prevalence of EKD increased progressively and was statistically significant as the number of traits of MS increased. Of the subjects with no traits, 2.9% met EKD criteria. The prevalence increased to 7.4% when a subject had 1 trait, to 9.5% with 2 traits, and to 20% when diagnosed with MS (P trend < .001). Table 3 shows that the healthy control subjects’ risk of EKD, estimated using odds ratio (OR), increased in connection with the number of traits of MS.

The prevalence of EKD increased progressively and was statistically significant as the number of traits of MS increased. Of the subjects with no traits, 2.9% met EKD criteria. The prevalence increased to 7.4% when a subject had 1 trait, to 9.5% with 2 traits, and to 20% when diagnosed with MS (P trend < .001). Table 3 shows that the healthy control subjects’ risk of EKD, estimated using odds ratio (OR), increased in connection with the number of traits of MS.

The prevalence of EKD increased progressively and was statistically significant as the number of traits of MS increased. Of the subjects with no traits, 2.9% met EKD criteria. The prevalence increased to 7.4% when a subject had 1 trait, to 9.5% with 2 traits, and to 20% when diagnosed with MS (P trend < .001). Table 3 shows that the healthy control subjects’ risk of EKD, estimated using odds ratio (OR), increased in connection with the number of traits of MS.

The prevalence of EKD increased progressively and was statistically significant as the number of traits of MS increased. Of the subjects with no traits, 2.9% met EKD criteria. The prevalence increased to 7.4% when a subject had 1 trait, to 9.5% with 2 traits, and to 20% when diagnosed with MS (P trend < .001). Table 3 shows that the healthy control subjects’ risk of EKD, estimated using odds ratio (OR), increased in connection with the number of traits of MS.

The prevalence of EKD increased progressively and was statistically significant as the number of traits of MS increased. Of the subjects with no traits, 2.9% met EKD criteria. The prevalence increased to 7.4% when a subject had 1 trait, to 9.5% with 2 traits, and to 20% when diagnosed with MS (P trend < .001). Table 3 shows that the healthy control subjects’ risk of EKD, estimated using odds ratio (OR), increased in connection with the number of traits of MS.

The prevalence of EKD increased progressively and was statistically significant as the number of traits of MS increased. Of the subjects with no traits, 2.9% met EKD criteria. The prevalence increased to 7.4% when a subject had 1 trait, to 9.5% with 2 traits, and to 20% when diagnosed with MS (P trend < .001). Table 3 shows that the healthy control subjects’ risk of EKD, estimated using odds ratio (OR), increased in connection with the number of traits of MS.

The prevalence of EKD increased progressively and was statistically significant as the number of traits of MS increased. Of the subjects with no traits, 2.9% met EKD criteria. The prevalence increased to 7.4% when a subject had 1 trait, to 9.5% with 2 traits, and to 20% when diagnosed with MS (P trend < .001). Table 3 shows that the healthy control subjects’ risk of EKD, estimated using odds ratio (OR), increased in connection with the number of traits of MS.
available in the literature. According to the EPIRCE (epidemiology of chronic renal failure in Spain) register, the prevalence of EKD in Spain may be around 2.2% in a population with an average age of 49 years old. The data from the present study would point to a much higher prevalence; however, given the characteristics of the sampling, it is not possible to estimate the population prevalence. In any case, it confirms that EKD is a common disease in Spain, especially in elderly subjects.

The prevalence of EKD in subjects with MS was significantly higher than in subjects without MS. Furthermore, the risk of EKD doubled when a subject had 1 criterion of MS, and progressively increased to 6.72 times higher in subjects with 3 or more traits. These data coincide with the data previously described for advanced KD, with an absolute risk difference of between 1.4 and 2.6. As far as we know, there are no data on the association between EKD and MS. The prevalence of EKD was notably higher in

<table>
<thead>
<tr>
<th>Traits</th>
<th>OR (95% CI)</th>
<th>Not adjusted</th>
<th>P</th>
<th>Adjusted for age and sex</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2.7 (1.39-5.22)</td>
<td>.003</td>
<td>2.3 (1.18-4.48)</td>
<td>.014</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>3.5 (1.8-6.81)</td>
<td>&lt;.001</td>
<td>2.98 (1.51-5.9)</td>
<td>.002</td>
<td></td>
</tr>
<tr>
<td>3 or more</td>
<td>8.4 (4.51-15.65)</td>
<td>&lt;.001</td>
<td>6.72 (3.56-12.09)</td>
<td>&lt;.001</td>
<td></td>
</tr>
</tbody>
</table>

CI, confidence interval; OR, odds ratio.

![Prevalence of EKD (%)](image)

**Figure 1.** Prevalence of early kidney disease in the general population for age groups and presence of metabolic syndrome. EKD, early kidney disease; MS, metabolic syndrome.

The prevalence of EKD in subjects with MS was significantly higher than in subjects without MS. Furthermore, the risk of EKD doubled when a subject had 1 criterion of MS, and progressively increased to 6.72 times higher in subjects with 3 or more traits. These data coincide with the data previously described for advanced KD, with an absolute risk difference of between 1.4 and 2.6. As far as we know, there are no data on the association between EKD and MS. The prevalence of EKD was notably higher in

<table>
<thead>
<tr>
<th>Factor</th>
<th>OR (95% CI)</th>
<th>Not adjusted</th>
<th>P</th>
<th>Adjusted for age and sex</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obesity</td>
<td>2.54 (1.76-3.65)</td>
<td>&lt;.001</td>
<td>2.31 (1.18-3.34)</td>
<td>&lt;.001</td>
<td></td>
</tr>
<tr>
<td>e-Tg</td>
<td>3.26 (2.25-4.71)</td>
<td>&lt;.001</td>
<td>3.21 (2.19-4.68)</td>
<td>&lt;.001</td>
<td></td>
</tr>
<tr>
<td>l-HDL</td>
<td>1.11 (0.72-1.72)</td>
<td>.616</td>
<td>1.14 (0.73-1.77)</td>
<td>.543</td>
<td></td>
</tr>
<tr>
<td>e-Gly</td>
<td>2.12 (1.48-3.04)</td>
<td>&lt;.001</td>
<td>1.73 (1.19-2.51)</td>
<td>&lt;.004</td>
<td></td>
</tr>
<tr>
<td>h-BP</td>
<td>3.43 (2.34-5.02)</td>
<td>&lt;.001</td>
<td>2.94 (1.98-4.35)</td>
<td>&lt;.001</td>
<td></td>
</tr>
<tr>
<td>IR</td>
<td>2.58 (1.68-3.98)</td>
<td>&lt;.001</td>
<td>2.37 (1.53-3.67)</td>
<td>&lt;.001</td>
<td></td>
</tr>
</tbody>
</table>

CI, confidence interval; e-Gly, elevated basal glycemia according to the criteria of metabolic syndrome; e-Tg, elevated triglycerides according to criteria of metabolic syndrome; h-BP, high blood pressure according to the criteria of metabolic syndrome; IR, insulin resistance; l-HDL, low value of high-density lipoproteins according to the criteria of metabolic syndrome; OR, odds ratio.

<table>
<thead>
<tr>
<th>Factor</th>
<th>OR (95% CI)</th>
<th>Not adjusted</th>
<th>P</th>
<th>Adjusted for age and sex</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Second quartile</td>
<td>1.08 (0.48-2.42)</td>
<td>.818</td>
<td>0.99 (0.44-2.23)</td>
<td>.991</td>
<td></td>
</tr>
<tr>
<td>Third quartile</td>
<td>2.62 (1.31-5.23)</td>
<td>.006</td>
<td>2.55 (1.26-5.15)</td>
<td>&lt;.001</td>
<td></td>
</tr>
<tr>
<td>Fourth quartile</td>
<td>4.29 (2.22-8.3)</td>
<td>&lt;.001</td>
<td>3.89 (1.99-7.59)</td>
<td>&lt;.001</td>
<td></td>
</tr>
</tbody>
</table>

CI, confidence interval; OR, odds ratio; first quartile, <1.21 (mU × mmol)/l; second quartile, 1.21-2.01 (mU × mmol)/l; third quartile, 2.02-3.21 (mU × mmol)/l; fourth quartile, >3.21 (mU × mmol)/l.
subjects with MS in all age groups. In addition, the difference between both prevalence rates is more significant in each age group compared to the previous one. It must be noted that there was a prevalence of 26.3% for EKD in subjects over 60 years old with MS. This shows the synergistic effect of age and MS on the deterioration of kidney function. Therefore, and given the high prevalence of MS in Spain, we believe that a large number of patients at high risk of EKD could be selected for a combined measurement of glomerular filtration rate and ACR.

It was found when assessing each trait of MS that all of them, except for low level of HDL, were associated with a high OR of EKD. Although it is well documented that low level of HDL is a risk factor for the deterioration of the glomerular filtration rate, its association with the presence of microalbuminuria has not been proven.

The presence of high levels of triglycerides tripled the risk of EKD. This association is described for advanced KD, with an OR of between 1.34 and 1.65. Although it is well documented that low level of HDL is a risk factor for the deterioration of the glomerular filtration rate, its association with the presence of microalbuminuria has not been proven.

The results of this study indicate that there is a significant association between minimal changes in blood pressure and initial deterioration of kidney function.

The results of this study indicate that there is a significant connection between the level of IR and the prevalence of EKD. As the HOMA value increased, the prevalence of EKD increased, from 4.2% in the first quartile to 15.7% in the fourth quartile. In addition, the risk of EKD in subjects with IR was significantly higher compared with insulin-sensitive subjects. The connection between advanced KD and IR can be gathered from some population-based studies, but its association with EKD had not been reported.

Carotid IMT is a useful and noninvasive method of assessing early carotid arteriosclerosis and is even considered a predictor of vascular events. The data of this study show that patients with EKD have a significantly increased carotid IMT, compared to healthy subjects. In the multivariate analysis adjusted for age and sex, EKD acted as an independent risk marker in the development of subclinical arteriosclerosis even after adjusting for MS. Preliminary studies by our group had indicated that EKD could be associated with an increased carotid IMT. These results reinforce the idea that KD, even in early stages, favors arterial disease well before symptoms associated with kidney deterioration can be seen.

Figure 2. Carotid intima-media thickness in patients with metabolic syndrome and kidney damage.
made it difficult to find differences between both groups, as this bias would tend to zero. Therefore, a stricter classification of the population would most likely show even more convincing data. A recent publication states that sex could be an important factor in the appearance of stage 1 to 5 kidney disease in patients with MS. This association has not been considered in this study and therefore, future studies could clarify these results. Validated markers to measure the socioeconomic level of the study population were not available.

CONCLUSIONS

MS is an important risk marker for EKD. Accordingly, its pathophysiology, IR, and all its traits, except for low level of HDL, are consistently associated with a higher prevalence of EKD. Furthermore, the coexistence of EKD in MS patients significantly increases the risk of thickened carotid IMT, compared to those without EKD.

CONFLICTS OF INTEREST

None declared.

REFERENCES


6. Ruilope LM, Van Veldhuisen DJ, Ritz E, Luscher TF. Renal function: the Cinderella factor in the appearance of stage 1 to 5 kidney disease in patients with MS. This association has not been considered in this study and therefore, future studies could clarify these results. Validated markers to measure the socioeconomic level of the study population were not available.

CONCLUSIONS

MS is an important risk marker for EKD. Accordingly, its pathophysiology, IR, and all its traits, except for low level of HDL, are consistently associated with a higher prevalence of EKD. Furthermore, the coexistence of EKD in MS patients significantly increases the risk of thickened carotid IMT, compared to those without EKD.

CONFLICTS OF INTEREST

None declared.

REFERENCES


6. Ruilope LM, Van Veldhuisen DJ, Ritz E, Luscher TF. Renal function: the Cinderella factor in the appearance of stage 1 to 5 kidney disease in patients with MS. This association has not been considered in this study and therefore, future studies could clarify these results. Validated markers to measure the socioeconomic level of the study population were not available.

CONCLUSIONS

MS is an important risk marker for EKD. Accordingly, its pathophysiology, IR, and all its traits, except for low level of HDL, are consistently associated with a higher prevalence of EKD. Furthermore, the coexistence of EKD in MS patients significantly increases the risk of thickened carotid IMT, compared to those without EKD.

CONFLICTS OF INTEREST

None declared.

REFERENCES


6. Ruilope LM, Van Veldhuisen DJ, Ritz E, Luscher TF. Renal function: the Cinderella factor in the appearance of stage 1 to 5 kidney disease in patients with MS. This association has not been considered in this study and therefore, future studies could clarify these results. Validated markers to measure the socioeconomic level of the study population were not available.

CONCLUSIONS

MS is an important risk marker for EKD. Accordingly, its pathophysiology, IR, and all its traits, except for low level of HDL, are consistently associated with a higher prevalence of EKD. Furthermore, the coexistence of EKD in MS patients significantly increases the risk of thickened carotid IMT, compared to those without EKD.

CONFLICTS OF INTEREST

None declared.

REFERENCES


6. Ruilope LM, Van Veldhuisen DJ, Ritz E, Luscher TF. Renal function: the Cinderella factor in the appearance of stage 1 to 5 kidney disease in patients with MS. This association has not been considered in this study and therefore, future studies could clarify these results. Validated markers to measure the socioeconomic level of the study population were not available.